AdasuveTreatment for Agitation, Schizophrenia, Bipolar Disorder
Update: Adasuve (loxapine) Now FDA Approved - December 21, 2012
Alexza Announces Extension of the Adasuve PDUFA Goal Date by Three Months
MOUNTAIN VIEW, Calif., January 23, 2012, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for Adasuve (Staccato loxapine).
In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) date for the Adasuve NDA has been extended from February 4, 2012 to May 4, 2012.
The FDA notified Alexza that its January 10, 2012 submission to the NDA, updating the proposed Risk Evaluation and Mitigation Strategy (REMS) program, has been designated as a major amendment. The FDA exercised its option to extend the PDUFA goal date to provide time to complete the review when a sponsor submits materials the FDA considers a major amendment to an NDA within three months of the PDUFA goal date. Alexza has submitted this amendment to the NDA, among others, to address topics discussed during the December 12, 2011 Psychopharmacologic Drugs Advisory Committee meeting on the Adasuve application.
"We continue to believe that we are on a pathway to gain approval of Adasuve in the United States," stated Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals. "We appreciate the efforts of the FDA to complete their review of our NDA and we will continue to support the continued review of the NDA."
Adasuve is an anti-agitation product candidate that combines Alexza's proprietary system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. Click here to see an animation of how the system works. In clinical studies, Adasuve has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The Adasuve NDA contains efficacy and safety data from more than 1,600 patients and subjects, who have been studied in thirteen different clinical trials.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato((R)) system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
Adasuve (loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the Adasuve NDA in December 2009. In October 2010, the Company received a Complete Response Letter from the FDA regarding the application. The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011. The Adasuve NDA was resubmitted in August 2011, completed an advisory committee meeting in December 2011, received a notice of extension of the Prescription Drug User Fee Act (PDUFA) goal date in January 2012, and has a new Prescription Drug User Fee Act (PDUFA) goal date of May 4, 2012.
In October 2011, the Company established a commercial partnership for Adasuve with Grupo Ferrer Internacional, S.A. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of Adasuve in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Alexza filed its Adasuve Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.
For more information about Alexza, the system technology or the Company's development programs, please visit www.alexza.com.
CONTACT: Thomas B. King, President and CEO, +1-650-944-7634, firstname.lastname@example.org
Web site: http://www.alexza.com/
Ticker Symbol: (NASDAQ-NMS:ALXA)
Terms and conditions of use apply
Copyright © 2012 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: January 2012
- FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults - December 21, 2012
- Alexza Announces Adasuve (Staccato Loxapine) PDUFA Goal Date of December 21, 2012 - July 6, 2012
- Alexza Receives Complete Response Letter for Adasuve NDA - May 3, 2012
- Alexza Announces the Adasuve (Staccato Loxapine) PDAC Meeting Date of December 12, 2011 - November 6, 2011
- Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012 - August 19, 2011
- Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA - August 5, 2011
- Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato Loxapine) NDA - January 18, 2011
- Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato Loxapine) - December 7, 2010
- Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA - October 11, 2010
- Alexza Announces AZ-004 (Staccato Loxapine) PDUFA Goal Date of October 11, 2010 - February 18, 2010
- Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004 - February 10, 2010
- Alexza Announces Submission of AZ-004 (Staccato Loxapine) NDA - December 15, 2009